title: The clinical implication of changing unbound quinidine levels.
abstract: Pharmacodynamic and pharmacokinetic aspects pertinent to the potential clinical application of unbound quinidine levels were studied. Following heparin administration during electrophysiologic testing in 10 patients receiving quinidine, there were significant increases in the mean (+/- SD) right ventricular effective refractory period (266 +/- 24 versus 279 +/- 23; p less than 0.025), free fatty acid concentration (515 +/- 213 versus 1071 +/- 359 mmol/L; p less than 0.001), and unbound quinidine concentration (0.3 +/- 0.1 to 0.6 +/- 0.1 microgram/ml; p less than 0.001) but no changes in heart rate, corrected QT interval, or total plasma quinidine concentration. Ten control patients showed no change in the right ventricular effective refractory period following heparin administration. These findings were consistent with a heparin-induced increase in unbound drug concentration and activity that was limited to the vascular compartment. Eleven patients studied on day 3 (+/- 1) and day 10 (+/- 3) during an acute myocardial infarction showed a significant decrease in unbound quinidine fraction (12 +/- 4% versus 9 +/- 4%; p less than 0.02) accompanied by a decrease, rather than the predicted increase, in half-life (7.1 +/- 2.7 versus 6.3 +/- 2.1 hours; p less than 0.02). Volumes of distribution remained stable while the mean quinidine clearance tended to increase. Half-life correlated with albumin changes (r = -0.71; p less than 0.02). Apparently, improvement in clinical status (assumed) and drug clearance (measured) negated the direct effects of the decrease in unbound quinidine fraction. Although unbound drug concentrations should correlate best with drug dynamic and kinetic information, full knowledge of the clinical context of such measurements is needed for appropriate interpretation.
authors.affiliation: Veterans Administration Medical Center, Miami, FL.
authors.forename: K M
authors.initials: KM
authors.lastname: Kessler
authors.forename: P M
authors.initials: PM
authors.lastname: Wozniak
authors.forename: D
authors.initials: D
authors.lastname: McAuliffe
authors.forename: E
authors.initials: E
authors.lastname: Terracall
authors.forename: P
authors.initials: P
authors.lastname: Kozlovskis
authors.forename: I
authors.initials: I
authors.lastname: Mahmood
authors.forename: L
authors.initials: L
authors.lastname: Zaman
authors.forename: R G
authors.initials: RG
authors.lastname: Trohman
authors.forename: A
authors.initials: A
authors.lastname: Castellanos
authors.forename: R J
authors.initials: RJ
authors.lastname: Myerburg
mesh_terms: D000328:Adult; D000368:Aged; D005230:Fatty Acids, Nonesterified / Q000097:blood; D006207:Half-Life; D006339:Heart Rate / Q000187:drug effects; D006493:Heparin / Q000494:pharmacology; D006801:Humans; D008049:Lipase / Q000097:blood; D008297:Male; D008875:Middle Aged; D009200:Myocardial Contraction / Q000187:drug effects; D009203:Myocardial Infarction / Q000097:blood / Q000503:physiopathology; D011802:Quinidine / Q000493:pharmacokinetics* / Q000494:pharmacology; D012032:Refractory Period, Electrophysiological / Q000187:drug effects
chemical_list: D005230:Fatty Acids, Nonesterified; D006493:Heparin; D008049:Lipase; D011802:Quinidine